Dianthus Therapeutics, Inc.
DNTHNASDAQHealthcareBiotechnology
As of Oct 16, 2026 close
- Market cap
- $4.17B
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $32.22$117.88
- Volume (live)
- -
- Avg. volume (3M)
- 927.58K
Dianthus Therapeutics (DNTH) Stock Price & Financial Analysis
Dianthus Therapeutics Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $69.43 - $75.34 |
|---|---|
| 52-Week High | $117.88 |
| 52-Week Low | $32.22 |
| Open | $74.41 |
| Volume (last close) | 1.05M |
| Average Volume (3M) | 927.58K |
| Revenue (TTM) | 1.90M |
|---|---|
| Net Income (TTM) | -29.91M |
| Free Cash Flow (TTM) | -155.71M |
| EPS (TTM) | −$0.67 |
| Profit Margin | -1570.85% |
| Operating Margin | -11441.39% |
| Return on Equity (ROE) | -2.55% |
| Debt to Equity | 0.00 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Market Cap | 4.17B |
|---|---|
| Shares Outstanding | 56.03M |
| Price to Sales (P/S) | 2189.08 |
| Price to Book (P/B) | 3.56 |
| EV/EBITDA | -99.71 |
| 50-Day MA | $100.83 |
|---|---|
| 200-Day MA | $82.74 |
| 1-Year Change | +108.67% |
Source: Market prices and company fundamentals. Data as of Oct 16, 2026. Data sources and methodology
Dianthus Therapeutics at a Glance
As of the Oct 16, 2026 close, Dianthus Therapeutics (DNTH) has a market capitalization of $4.17B. The stock trades at 2189.1× sales. Over the trailing twelve months it lost $29.91M on revenue of $1.90M and burned $155.71M of free cash flow. Revenue fell 60.8% year over year.
As of its latest reported balance sheet, it holds $110.55M in cash and securities against $1.29M of debt, a net cash position of $109.26M.
Dianthus Therapeutics does not currently pay a dividend.
The share price is up 108.7% over the past year. At $72.09 (the Oct 16, 2026 close) it sits within its 52-week range of $32.22 to $117.88, below its 200-day moving average of $82.74.
Based on 13 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $142.82, 98.1% above the Oct 16, 2026 close.
Frequently Asked Questions About Dianthus Therapeutics
What is the current stock price for DNTH?
As of the Oct 16, 2026 close, DNTH stock trades at $72.09. The 52-week range is $32.22–$117.88, with a day range of $69.43–$75.34.
What is the P/E ratio for DNTH?
The P/E ratio (Price-to-Earnings) for DNTH is shown in the Key Statistics section. This valuation metric helps compare Dianthus Therapeutics, Inc. to industry peers.
Does DNTH pay dividends?
Dianthus Therapeutics does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for DNTH?
Based on ratings from 13 professional analysts over the last 90 days, the consensus for DNTH is Buy. The average 12-month price target is $142.82, a 98.1% upside from the Oct 16, 2026 close of $72.09.
What is the market cap of DNTH?
As of the Oct 16, 2026 close, Dianthus Therapeutics's market capitalization is $4.04B, classifying it as a mid-cap company. Dianthus Therapeutics operates in the Healthcare sector within the Biotechnology industry.